Positive News SentimentPositive NewsNASDAQ:XNCR Xencor (XNCR) Stock Price, News & Analysis $7.74 +0.19 (+2.52%) Closing price 05/29/2025 04:00 PM EasternExtended Trading$7.68 -0.07 (-0.84%) As of 05/29/2025 06:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Xencor Stock (NASDAQ:XNCR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Xencor alerts:Sign Up Key Stats Today's Range$7.55▼$7.8250-Day Range$7.52▼$11.8252-Week Range$7.16▼$27.24Volume1.12 million shsAverage Volume659,852 shsMarket Capitalization$550.86 millionP/E RatioN/ADividend YieldN/APrice Target$29.50Consensus RatingModerate Buy Company OverviewXencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.Read More… Xencor Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks80th Percentile Overall ScoreXNCR MarketRank™: Xencor scored higher than 80% of companies evaluated by MarketBeat, and ranked 201st out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingXencor has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 7 buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageXencor has only been the subject of 3 research reports in the past 90 days.Read more about Xencor's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Xencor are expected to grow in the coming year, from ($3.68) to ($3.64) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Xencor is -2.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Xencor is -2.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioXencor has a P/B Ratio of 0.70. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Xencor's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.28% of the float of Xencor has been sold short.Short Interest Ratio / Days to CoverXencor has a short interest ratio ("days to cover") of 9.5.Change versus previous monthShort interest in Xencor has recently increased by 9.44%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldXencor does not currently pay a dividend.Dividend GrowthXencor does not have a long track record of dividend growth. Sustainability and ESG3.9 / 5Environmental Score-2.24 Percentage of Shares Shorted13.28% of the float of Xencor has been sold short.Short Interest Ratio / Days to CoverXencor has a short interest ratio ("days to cover") of 9.5.Change versus previous monthShort interest in Xencor has recently increased by 9.44%, indicating that investor sentiment is decreasing significantly. News and Social Media3.7 / 5News Sentiment1.72 News SentimentXencor has a news sentiment score of 1.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Xencor this week, compared to 3 articles on an average week.Search Interest1 people have searched for XNCR on MarketBeat in the last 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Xencor insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $50,914.00 in company stock.Percentage Held by InsidersOnly 4.76% of the stock of Xencor is held by insiders.Read more about Xencor's insider trading history. Receive XNCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Xencor and its competitors with MarketBeat's FREE daily newsletter. Email Address XNCR Stock News HeadlinesXencor, Inc. (NASDAQ:XNCR) EVP Nancy Valente Sells 4,616 SharesMay 7, 2025 | insidertrades.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Clover Health Investments (CLOV), Xencor (XNCR) and Intellia Therapeutics (NTLA)May 13, 2025 | theglobeandmail.comHow I make 💰 trading from 135 countries I’ve traveled to 135 countries… In a new time zone almost every week… (Often 8… 12… 16 hours AHEAD of the United States) And yet I’ve made $7.9 million career profits… trading in the US markets?May 30, 2025 | Timothy Sykes (Ad)Xencor Reports First Quarter 2025 Financial ResultsMay 7, 2025 | uk.finance.yahoo.comWilliam Blair starts Xencor stock with Outperform ratingApril 23, 2025 | uk.investing.comWilliam Blair Initiates Coverage of Xencor (XNCR) with Outperform RecommendationApril 22, 2025 | msn.comXencor initiated with an Outperform at William BlairApril 21, 2025 | markets.businessinsider.comXencor participates in a conference call with JPMorganApril 19, 2025 | markets.businessinsider.comSee More Headlines XNCR Stock Analysis - Frequently Asked Questions How have XNCR shares performed this year? Xencor's stock was trading at $22.98 on January 1st, 2025. Since then, XNCR shares have decreased by 66.3% and is now trading at $7.74. View the best growth stocks for 2025 here. How were Xencor's earnings last quarter? Xencor, Inc. (NASDAQ:XNCR) released its quarterly earnings data on Thursday, May, 8th. The biopharmaceutical company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.60) by $0.06. Xencor's revenue for the quarter was up 104.6% compared to the same quarter last year. Who are Xencor's major shareholders? Xencor's top institutional shareholders include Primecap Management Co. CA (13.72%), Vanguard Group Inc. (11.10%), Price T Rowe Associates Inc. MD (5.52%) and BVF Inc. IL (3.85%). Insiders that own company stock include Bassil I Dahiyat, John R Desjarlais, John J Kuch, Allen Yang, Nancy Valente, Celia Eckert, Alan Bruce Montgomery and Kurt A Gustafson. View institutional ownership trends. How do I buy shares of Xencor? Shares of XNCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Xencor own? Based on aggregate information from My MarketBeat watchlists, some other companies that Xencor investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), AUO (AUOTY) and DiamondRock Hospitality (DRH). Company Calendar Last Earnings5/08/2025Today5/30/2025Next Earnings (Estimated)8/04/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:XNCR CIK1326732 Webwww.xencor.com Phone(626) 305-5900Fax626-305-0350Employees280Year FoundedN/APrice Target and Rating Average Stock Price Target$29.50 High Stock Price Target$40.00 Low Stock Price Target$6.00 Potential Upside/Downside+281.1%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($3.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$126.09 million Net Margins-232.77% Pretax Margin-229.85% Return on Equity-30.92% Return on Assets-21.74% Debt Debt-to-Equity Ratio0.01 Current Ratio6.23 Quick Ratio6.23 Sales & Book Value Annual Sales$127.23 million Price / Sales4.33 Cash FlowN/A Price / Cash FlowN/A Book Value$10.99 per share Price / Book0.70Miscellaneous Outstanding Shares71,171,000Free Float66,322,000Market Cap$550.86 million OptionableOptionable Beta0.99 Social Links 2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:XNCR) was last updated on 5/30/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredElon Musk’s Frightening Warning Forces Trump’s HandElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | SponsoredUrgent: Make this trade before you hit your pillow tonight… Most people waste 8 hours every night… And 227,916 hours in their lifetime… Dreaming about the life they...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xencor, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xencor With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.